The diagnosis and management of hypotension in the very low birth weight (VLBW) is a controversial area.
Introduction
There are no uniform criteria for the diagnosis of hypotension in the very low birth weight (VLBW) infant. 1 A number of statistically defined normative blood pressure ranges do exist, which are based on gestational age, birth weight and postnatal age. [2] [3] [4] [5] These absolute values are frequently relied on for intervention. However, although blood pressure is only one aspect of cardiovascular status, and may not directly correlate with tissue perfusion, it is frequently relied on because cardiac output and vascular resistance are very difficult to measure in the newborn. Is it possible to determine overall perfusion clinically and accurately, are nonspecific clinical signs of cardiovascular status important, and if so, do neonatologists incorporate them when deciding to intervene in states of low blood pressure? These questions to date remain unanswered.
Many different therapeutic algorithms for hypotension treatment exist. 6, 7 These typically consist of initial volume expansion, followed by inotropic support and, more recently, corticosteroids in cases of 'vasopressor resistant hypotension'. The primary vasopressor-inotrope recommended in many of these regimes remains dopamine, despite the fact that there is little evidence for this approach. Dobutamine is also frequently used, despite the fact that, as a vasodilator, it is often ineffective at elevating blood pressure but may well be better than dopamine at improving systemic blood flow. 8 Epinephrine is often reserved as a third-or fourth-line agent.
Whereas there is evidence of an association between hypotension and neurological injury, 9 there is no evidence that treatment aimed at improving systemic blood pressure results in any improvement in clinically important outcomes, such as a reduction in the incidence of intraventricular hemorrhage, periventricular leukomalacia or improved long-term neurological results. 10 Improved understanding of current practice will inform the design of future prospective studies to address these issues. The primary aim of this questionnaire study was to (i) identify current practices regarding the criteria used to define hypotension and (ii) determine the main approaches to circulatory support in the VLBW infant during the first 72 h of life, among neonatologists in Canada.
Methods
An 18-item questionnaire was sent to neonatologists practicing in level 2 and 3 neonatal intensive care units across Canada. Participants were identified from a registry of the Canadian Pediatric Society. This questionnaire was anonymous and participation was entirely voluntary. Ethical approval for this study was obtained from our institutional research ethics board. A cover letter was sent with each questionnaire, noting that participation was voluntary and anonymous, as well as a stamped address envelope in which to return completed questionnaires. Returned completed questionnaires from each physician were taken as consent to participate in the study. The questionnaire consisted of 18 questions. These addressed criteria used to define hypotension and its subsequent management in the VLBW infant during the first 72 h of life. Questions investigated the diagnostic criteria used to diagnose hypotension, including gestational age-or weight-based normal values and whether blood pressure data alone were used, or a combination of clinical signs and normal values. Specific questions relating to management addressed which agent was used first after hypotension had been diagnosed, and which were used as second or third choices. Participants were given an option of volume, vasopressor-inotrope, inotrope or steroid. The specific agent, including starting doses and subsequent dosing regimes of each were also addressed, as was the use of sodium bicarbonate. Demographic details were obtained on the participants including the number of years they were in practice and also the number of VLBW infants they cared for annually. A copy of the questionnaire can be obtained from the author on request. The questionnaire was subsequently resent 4 months later, again with a cover letter and a stamped addressed envelope.
Results
A total of 120 questionnaires were sent. Ninety-five replies were received, a response rate of 79%. Two people declined to participate as they had retired from clinical involvement. Therefore, 93 valid questionnaires were returned.
Participants
Seventy-seven percent of respondents work in units where at least 50 VLBWs are cared for annually, and 43% where at least 100 VLBWs are cared for annually. Fifty-seven percent of the respondents have at least 10 years experience as practicing neonatologists.
Diagnostic criteria 25.8% of the respondents rely on absolute blood pressure values alone when defining hypotension, the remainder stating that they combine blood pressure values and clinical signs of perfusion (color, capillary refill time and urine output). The most commonly used (87.1%) blood pressure standard is a blood pressure in mm Hg less than gestational age in weeks, as defined by the BAPM. 5 Other criteria included Wakins 4 weight-based criteria, Zubrows 3 criteria and a cutoff blood pressure value of 30 mm Hg (3%).
Individual agents
Volume is the primary agent administered in 97% of cases, normal saline being the primary agent used by over 95%. Plasma and albumin were the other agents used initially. Five of the respondents stated that they would administer blood if there was a definite sign of blood loss. The initial median dose of saline administered was 10 mls/kg (range 10-20 mls/kg). The maximum median dose was 20 mls/kg (range 10-40 mls/kg). Thirty percent of the respondents would administer a maximum dose of 10 mls/kg before commencing an inotrope if there was no obvious sign of volume loss. Dopamine is the most common vasopressor-inotrope used. The median starting dose is 5 mcg/kg/min (range 2.5-10 mcg/kg/ min). The median time interval allowed before increasing the dose is 15 min and the usual dose increment is 2.5 mcg/kg/min. The median maximum dose is 20 mcg/kg/min (range 10-30 mcg/kg/ min). The maximum dose for seven respondents is the same as the initial starting dose for 17 others.
Dobutamine was used by 43%. The median (range) starting dose was 5 mcg/kg/min (range 2-10 mcg/kg/min). The median incremental increase was 5 mcg/kg/min, with a median wait time of 30 min before increasing the dose. The maximum median (range) dose was 20 mcg/kg/min (range 10-20 mcg/kg/min).
Sixty-two percent of neonatologists would employ epinephrine as an agent in the hypotensive VLBW, albeit most commonly as a third-or fourth-line agent. A few are using epinephrine as the firstline therapeutic intervention. Great variation exists in both the starting dose and the maximum dose of epinephrine. The starting dose varied from 0.01 to 0.1, median 0.05 mcg/kg/min with a maximum dose of 0.4-4.0, median 1.0 mcg/kg/min.
Hydrocortisone is the steroid of choice. It is the most popular drug prescribed following dopamine. Great variation exists in the starting dose and the maximum daily dose that would be prescribed (see Table 1 ). Of particular note, some respondents start hydrocortisone at a dose, 5 mg/kg, which is 10 Â higher than the maximum dose for others.
Therapeutic regimes
Volume followed by dopamine is by far the most common regime used (91% of the respondents). Three predominant patterns of treatment exist. These include (i) volume, dopamine, steroid (32%), (ii) volume, dopamine, dobutamine (29%), (iii) volume, dopamine, epinephrine (22%). There are a number of other regimes used that include different combinations of the above agents; some of these include a vasopressor-inotrope initially, either dopamine or epinephrine without the administration of any volume (see Figure 1) . Only 14% have management protocols in place to guide treatment options for hypotension. Six percent of the respondents volunteered that they avail of echocardiography to assist them in their decision making.
Discussion
This is the first large study of practices amongst neonatologists addressing diagnosis and management of hypotension in the VLBW infant. We found three quarters of the participants included clinical signs (capillary refill, color, urine output) when deciding whether a patient is deemed hypotensive or not. Individually these may be unreliable indicators of circulatory status but collectively and with blood pressure data may be a better indicator of systemic blood flow than simply absolute blood pressure values alone. 11 Osburn et al. 12 has shown that combining blood pressure data and capillary refill times are better indicators of systemic flow than either alone.
There is large variation in normal blood pressure values available in the literature. These variations are due to differences in methodology, including retrospective data collection, small number of patients included, combined invasive and non-invasive measurements, inclusion of small and appropriate for gestational age infants and collection of only a few data points. Some studies have averaged blood pressure obtained over several postnatal hours, which, with the well-described spontaneous postnatal elevation in blood pressure, provides misleading information. We found the most frequently used criteria were a mean blood pressure less than gestational age in weeks, 5 followed by Watkins criteria 4 and Zubrows criteria. 3 Although some of these normal ranges were derived statistically, there is no evidence that they should serve as a threshold to commence therapy. Using these statistically derived values as a guide and including clinical signs in the decision making before intervention appears to be widely accepted in Canada, 75% of respondents using such an approach.
Volume boluses are the initial intervention used by the large majority of respondents, almost all in the form of normal saline. There appears to be a growing recognition that for the most part these patients are not hypovolemic 13 and that volume administration may in fact be detrimental. [14] [15] [16] Supporting evidence for the lack of importance of hypovolemia is the lack of response to volume administration. 17, 18 Recent therapeutic algorithms have suggested limiting volume administration to 10 ml/kg. 19 Almost 30% of our respondents limit the amount of volume administered to 10 mls/kg before moving on to inotropic agents and a small percentage will start with an inotrope unless there is an obvious reason to administer volume. Other surveys have shown a very wide range in fluid bolus administration, with some consultants in the UK limiting the total volume to 20 ml/kg and others prepared to give 60 ml/kg. 20 Three predominant regimes currently exist in practice, each consists of volume, dopamine and subsequently either steroid, epinephrine or dobutamine. The evidence supporting any of these regimes is lacking. We know that dopamine effectively increases blood pressure but carries the risk of inducing inappropriate increases in systemic vascular resistance which may lead to decreases in cardiac output. 8, 21 Dobutamine is frequently ineffective at increasing blood pressure, but appears to improve cardiac output and end-organ flow 8 and may be the most appropriate agent used in documented myocardial dysfunction. Epinephrine may increase both blood pressure and cardiac output 22 but data are limited. However, there is little or no data regarding clinically important outcomes, including long-term follow-up, available for any of these Figure 1 Therapeutic algorithms stated by participants for management of hypotension in the VLBW infant.
agents. Steroids have become a popular choice in the therapeutic algorithm and are now the most common agent added following dopamine and in some instances are used before an inotrope. We know that steroids will improve blood pressure in hypotensive newborns, 23 and reduce the use of other agents, but there are potential adverse short-term effects and no evidence that clinically important outcomes are improved. Also disturbing is the dramatic variation in steroid doses that are being used, with tenfold dosing differences noted. In particular, the starting dose of steroid ranges from 0.1 to 5 mg/kg with daily doses ranging from 0.6 to 20 mg/kg. This wide variation in dosing is also to be seen in a number of randomized studies evaluating the effectiveness of steroids in the treatment of hypotension. 24, 25 This variation in dosing schedule can also be seen with any of the inotropic/pressor agents prescribed in this study.
There are some limitations to this type of questionnaire study. Despite a good overall response rate of 79%, it is possible that there is a non-responder bias. The questionnaire asked about the approach to the infant with a birth weight less than 1500 g and as such did not address specific gestational ages. The specific etiology of the hypotension was not addressed, however the majority of hypotensive preterm infants have no specific etiology, except in circumstances of obvious blood loss or obvious clinical sepsis. Furthermore, our primary interest was in the stated attitudes and approaches of neonatologists; we do not know whether this translates into actual bedside practice.
We believe that the current variation in approach relates to our poor understanding of normal circulatory function in the VLBW infant during this transitional time period and also to the lack of clinical evidence supporting the use of any particular approach to circulatory support. This results in clinical uncertainty and as a result marked variation in clinical practice. One of the main concerns this survey highlights is the popularity of corticosteroid as a therapeutic intervention, despite the incidence of short-term and potential long-term side effects. The appropriate management of hypotension in the VLBW infant remains uncertain. Multicenter studies comparing different therapeutic interventions with appropriate long-term follow-up are now clearly required.
